India, March 18 -- Actinium Pharmaceuticals, Inc. (ATNM) Tuesday has launched a clinical program evaluating Actimab-A in combination with the PD-1 inhibitors pembrolizumab - KEYTRUDA and nivolumab OPDIVO.
These immunotherapies generated $38.8 billion in 2024 across various solid tumor indications but face efficacy limitations due to Myeloid-Derived Suppressor Cells - MDSCs, which help tumors evade immune detection. Actimab-A targets CD33, an antigen expressed by MDSCs, aiming to enhance the effectiveness of PD-1 inhibitors by depleting these immune-suppressive cells.
The program includes controlled, head-to-head clinical trials comparing Actimab-A with PD-1 inhibitors versus PD-1 inhibitors alone in patients with head and neck squamous ce...